FATE Dividend History & Analysis | N/A Yield
FATE has a dividend yield of N/A and paid N/A per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Biotechnology
| Symbol | Market Cap USD | Dividend Yield TTM | Yield on Cost 5y |
|---|---|---|---|
| ABBV | 387,093 M | 3.34% | 7.54% |
| AMGN | 198,244 M | 3.21% | 5.93% |
| GILD | 176,133 M | 2.79% | 5.63% |
| HLN | 46,623 M | 1.76% | 2.46% |
| BIM | 13,627 M | 0.74% | 0.75% |
| Symbol | Market Cap USD | Growth Rate | Consistency |
|---|---|---|---|
| BTX | 1,425 M | 134% | 95.6% |
| HLN | 46,623 M | 30.1% | 100% |
| AMGN | 198,244 M | 7.84% | 100% |
| BIM | 13,627 M | 9.76% | 96.0% |
| ABBV | 387,093 M | 5.98% | 100% |
Quality Dividend Peers in Biotechnology
3.21% Yield
2.79% Yield
FATE Dividend History: as of February 2026
No dividends paid yet.FATE Dividend FAQ
Fate Therapeutics (NASDAQ:FATE) is a clinical-stage biopharma focused on off-the-shelf, iPSC-derived cellular immunotherapies for oncology and immune-mediated diseases. Its pipeline features CAR-NK/T candidates such as FT576 (multiple myeloma), FT836 (preclinical, multiple tumors), FT522 (B-cell lymphoma & autoimmunity), plus CAR-T programs FT819 (systemic lupus erythematosus) and FT825 (solid tumors). The company also holds a collaboration and option agreement with Ono Pharmaceutical to co-develop and commercialize iPSC-derived CAR-T products for solid tumors.
What is the Dividend Yield of FATE?
As of February 2026, FATE`s dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 1.14.Does FATE pay a dividend?
As of February 2026 FATE does not pay a dividend.How often does FATE pay dividends?
Over the last 12 months, FATE has issued dividend payments.FATE dividend forecast
Based on historical data, the forecasted dividends per share for FATE for the next 4 payments are between 0 (+0.0%) and 0 (+0.0%).This suggests the dividend will remain relatively stable.
Will FATE pay dividends in 2026?
The next Ex-Dividend date for Fate Therapeutics (FATE) is currently unknown.What is the next Ex-Dividend Date for FATE?
The next Ex-Dividend date for Fate Therapeutics (FATE) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.What is the Dividend Growth of FATE?
FATE's average dividend growth rate over the past 5 years is -% per year.
What is the Yield on Cost of FATE?
FATE's 5-Year Yield on Cost is -%. If you bought FATE's shares at 108.50 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.What is the Payout Consistency of FATE?
FATE Payout Consistency is 0.0%.
The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
Does FATE have a good Dividend Yield?
FATE`s % Dividend Yield is considered as unknown.What is the Dividend Payout Ratio of FATE?
The Dividend Payout Ratio of FATE is unknown.What is the Dividend Rating of FATE?
FATE`s Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.Key Metric Definitions
- Dividend Yield
- Annual dividend per share divided by current share price.
- Payout Ratio
- Percentage of earnings paid as dividends. Below 60% = safe, above 100% = unsustainable.
- Payout FCF
- Percentage of Free Cash Flow paid as dividends. More reliable than Payout Ratio since it measures actual cash.
- Growth Rate (CAGR)
- Compound annual growth rate of dividends over the last 5 years.
- Consistency
- Reliability of dividend payments over lifetime. Penalizes cuts and pauses.
- Yield on Cost
- Your effective yield if you bought 5 years ago. Shows dividend growth impact over time.
- Streak
- Consecutive years of dividend payments. 25+ years = Dividend Aristocrat.
- Dividend Rating
- Proprietary score (0-100) combining yield, growth, safety and consistency.
Last update: 2026-02-02 02:15